Dupilumab (DupixentTM) Now Available for Adolescents Aged 12 and Older
ESC is pleased to share that last fall, Health Canada approved dupilumab (brand name Dupixent™) for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescent patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
This news means renewed hope for adolescents who live with severe AD (commonly known as eczema) that don’t respond to current therapies. We often hear that adolescents living with eczema can experience low self-esteem, bullying, and isolation due their condition, as eczema can easily compound stressors already associated with the teen years.
As new treatment options arise, ESC continues to work tirelessly to meet with decision makers and improve patient access to new therapies such as dupilumab. We invite you to share your stories with us to help demonstrate the burden of this condition and the needs of our community.